Altuviiio™ (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl) – New orphan drug approval
February 22, 2023 - The FDA approved Bioverativ Therapeutics and Sanofi’s Altuviiio (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl).
Download PDF
